Key takeaways
- Retatrutide adds a glucagon receptor to tirzepatide's GIP and GLP-1. Three targets versus two.
- Tirzepatide is FDA approved. Retatrutide is not approved anywhere, and phase 3 is still running.
- Framing this as next-gen versus current assumes phase 3 succeeds. That assumption is the thing under test.
- Retatrutide has more lab records in our ledger (44) than tirzepatide (33), and a wider dose spread: up to 43.5% over label.
The framing does the work
"Three receptors versus two." Put like that, the answer seems obvious, and that's exactly why the pairing gets used to sell things.
So start with what actually separates them, which isn't receptor count.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors | GIP, GLP-1, glucagon | GIP, GLP-1 |
| Regulatory status | Not approved anywhere | FDA approved |
| Our evidence rating | Moderate, developing record | High, established record |
| Evidence stands at | Phase 2: 338 adults, 48 weeks | Completed trials and approval |
| Brand names | None. It has no approved product | Zepbound, Mounjaro |
| Lab records in our ledger | 44 | 33 |
| Vendors listing it | 3 | 2 |
| Listed package prices | $45.00 to $306.00 | $34.00 to $180.00 |
Ratings from our research directory. Prices from our price market, checked 25 July 2026.
One row matters more than all the others. One of these has been approved for use in people and the other hasn't.1
Why "next-gen versus current" smuggles in an assumption
The phrase treats retatrutide as tirzepatide's successor. Successors arrive; this one might not.
Calling something next-generation assumes phase 3 will confirm what phase 2 suggested. That assumption is precisely what phase 3 exists to test, and it isn't a formality. Compounds do fail at that stage, sometimes on durability, sometimes on harms that only appear at scale.
So the honest version of the comparison is a shape, not a ranking:
Tirzepatide has finished the process. The benefits and the risks are characterised well enough that a regulator authorized specific products for specific uses.
Retatrutide has a promising mid-stage result and an unfinished programme. That's a genuinely good position for an experimental compound and it isn't the same kind of thing.
Comparing them head to head implies they sit at the same stage of evidence. They don't, and that gap is larger than any difference in receptor count.
We built the evidence-maturity framework around this specific failure, where activity around a compound gets mistaken for maturity of evidence.
What the third receptor is actually for
The pharmacology is genuinely interesting, so it's worth explaining rather than dismissing.
Tirzepatide engages GIP and GLP-1, both hormones your gut releases after eating.2 Retatrutide adds the glucagon receptor.
Glucagon does roughly the opposite of insulin: it mobilises stored energy. Recruiting it deliberately is a bet on increasing energy expenditure rather than only reducing appetite.
That's a real mechanistic difference and a reasonable hypothesis. A reasonable hypothesis is not a result, and whether the third target translates into better outcomes for people is unresolved.
More on each: retatrutide and tirzepatide.
Where they differ in the vial
Both are sold by research vendors, and our ledger has enough records on each to say something.
| Across our published records | Retatrutide | Tirzepatide |
|---|---|---|
| Records with dose data | 40 | 33 |
| Identity confirmed | Every record | Every record |
| Purity range | 99.07% to 99.94% | 99.39% to 99.97% |
| Vials over labelled dose | 35 of 40 | 31 of 33 |
| Median variance | +11.1% | +13.1% |
| Widest miss | +43.5% | +22.8% |
Same story for both: identity and purity hold up, and the labelled dose doesn't.3
Retatrutide carries the widest single miss in our entire ledger. A vial sold as 10mg measured 14.35mg at 99.859% purity. Clean material, wrong amount by nearly half.
The odd detail is that the unapproved compound is the more heavily tested one. 44 records against 33, sold by 3 vendors against 2. Testing volume tracks how much something sells, not how well it's been studied.
The price gap says something too
Retatrutide spans $45.00 to $306.00 across 3 vendors. Tirzepatide spans $34.00 to $180.00 across 2.
That's a 6.8x spread against 5.3x, and retatrutide's ceiling is 70% higher.
Part of that is package size. Part of it is that there's no approved product to anchor an unapproved compound's price against, so nothing constrains what a seller asks.
Neither range says anything about quality, and both are package prices rather than cost per milligram.
How to actually think about it
Not as a choice between two comparable options, because they aren't comparable in the way the framing implies.
If the question is which has better evidence, tirzepatide, and not narrowly. Approval versus no approval is the largest evidence gap available.
If the question is which is more interesting pharmacologically, retatrutide has a real case, and interesting is not the same as established.
If the question is which to use, that's clinical, and one of the two isn't authorized for use at all.
The thing to resist is the upgrade narrative. Adding a receptor is a hypothesis, and finishing phase 3 is a result. Only one of these compounds has done the second thing.
Profiles with graded outcomes and sources: retatrutide and tirzepatide.
Frequently asked questions
Is retatrutide better than tirzepatide?
The evidence cannot support that claim. Tirzepatide has completed trials and FDA approval. Retatrutide has a randomized phase 2 result in 338 adults over 48 weeks and no approval anywhere. Comparing a mid-stage result against a completed programme is not a comparison of effectiveness, it is a comparison of how far each has got.
What is the actual difference between them?
Receptor count. Tirzepatide activates GIP and GLP-1. Retatrutide activates GIP, GLP-1, and glucagon receptors. The glucagon target is the addition, and whether it improves real outcomes is one of the questions phase 3 exists to answer.
Should I wait for retatrutide?
That is a clinical question rather than an informational one, and it depends on things no article knows about you. What we can say is that no regulator has authorized retatrutide, its long-term durability and safety are not established, and phase 3 programmes do sometimes fail to confirm phase 2 results.
Why is retatrutide already for sale if it isn't approved?
Because research-vendor sales do not wait for approval. Material is sold labelled for research use only, which is a legal category rather than a quality assurance. Our ledger holds 44 published lab records for retatrutide, more than for any approved peptide we track, which reflects sales volume rather than regulatory standing.
Read next
Educational information only. This article does not recommend a treatment, supplier, dose, or medical decision. See how we evaluate evidence.